Patents by Inventor Brian Leyland-Jones

Brian Leyland-Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Individualization of therapy with Alzheimer's disease agents
    Publication number: 20030138375
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with Alzheimer's disease agents.
    Type: Application
    Filed: June 6, 2002
    Publication date: July 24, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with antiarrhythmics
    Publication number: 20030124636
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiarrythmics.
    Type: Application
    Filed: April 17, 2002
    Publication date: July 3, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with antineoplastic agents
    Publication number: 20030108484
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antineoplastic agents.
    Type: Application
    Filed: April 29, 2002
    Publication date: June 12, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • ELISA kit for the determination of CYP2C19 metabolic phenotypes and uses thereof
    Publication number: 20030103901
    Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C19 (CYP 2C19). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C19 (CYP 2C19) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs metabolized by CYP 2C19 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.
    Type: Application
    Filed: April 23, 2002
    Publication date: June 5, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Multiple determinants for metabolic phenotypes
    Publication number: 20030091975
    Abstract: The invention relates to the determination of multiple phenotypic determinants for human drug metabolizing enzymes. More specifically, the present invention relates to the characterization of metabolic phenotypes based on phenotypic determinants and applications and uses thereof.
    Type: Application
    Filed: February 8, 2002
    Publication date: May 15, 2003
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with analgesics
    Publication number: 20030077222
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with analgesics.
    Type: Application
    Filed: May 7, 2002
    Publication date: April 24, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with erectile dysfunction agents
    Publication number: 20030073133
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with ED agents.
    Type: Application
    Filed: April 26, 2002
    Publication date: April 17, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with antidepressants
    Publication number: 20030072710
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antidepressants.
    Type: Application
    Filed: March 14, 2002
    Publication date: April 17, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with immunosuppressants
    Publication number: 20030068273
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with immunosuppressants.
    Type: Application
    Filed: March 14, 2002
    Publication date: April 10, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with hyperlipidemia agents
    Publication number: 20030053950
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with hyperlipidemia agents.
    Type: Application
    Filed: April 17, 2002
    Publication date: March 20, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with gastroesophageal reflux disease agents
    Publication number: 20030049204
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with GERD agents.
    Type: Application
    Filed: April 24, 2002
    Publication date: March 13, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Elisa kit for the rapid determination of N-acetyltransferase (NAT2) phenotypes
    Patent number: 5830672
    Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) kit for the rapid determination of N-acetyltransferase (NAT2) phenotype which can be used on a routine basis in a clinical laboratory. The ELISA kit allows physicians to: a) individualize therapy of drugs such as amrinone, procainamide, amonafide, dapsone, isoniazid, trimethoprim-sulphamethoxazole (TMP-SMX) and b) to predict susceptibility to carcinogen induced diseases such as bladder and colon rectal cancers.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: November 3, 1998
    Inventors: Irving W. Wainer, Pierre Wong, Brian Leyland-Jones